Literature DB >> 4608161

Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine.

A L Laaksonen, V Koskiahde, K Juva.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4608161     DOI: 10.3109/03009747409115809

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


× No keyword cloud information.
  31 in total

Review 1.  Management of rheumatic diseases in children.

Authors:  B H Athreya
Journal:  Indian J Pediatr       Date:  1996 May-Jun       Impact factor: 1.967

Review 2.  Medical management of children with juvenile rheumatoid arthritis.

Authors:  J T Cassidy
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

3.  Current management of juvenile arthritis.

Authors:  J Chaitow
Journal:  Indian J Pediatr       Date:  1986 Sep-Oct       Impact factor: 1.967

Review 4.  Juvenile rheumatoid arthritis: therapeutic perspectives.

Authors:  Ian C Chikanza
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 5.  A clinical and economic review of disease-modifying antirheumatic drugs.

Authors:  S E Gabriel; D Coyle; L W Moreland
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Inhibition of leucocyte motility and prevention of immune-complex experimental colitis by hydroxychloroquine.

Authors:  J M Rhodes; J E McLaughlin; D J Brown; L A Nuttall; D P Jewell
Journal:  Gut       Date:  1982-03       Impact factor: 23.059

Review 7.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

8.  Optimum Management of juvenile chronic polyarthritis.

Authors:  J J Calabro
Journal:  Drugs       Date:  1983-12       Impact factor: 9.546

9.  Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis.

Authors:  P Augustijns; P Geusens; N Verbeke
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 10.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.